Gilead Sciences (GILD) – Research Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Gilead Sciences (NASDAQ: GILD):

• 7/29/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/29/2026 – Gilead Sciences had its price target lowered by Barclays PLC from $155.00 to $145.00. They now have an “equal weight” rating on the stock.
• 7/27/2026 – Gilead Sciences had its price target lowered by Morgan Stanley from $166.00 to $165.00. They now have an “overweight” rating on the stock.
• 7/21/2026 – Gilead Sciences was downgraded by Leerink Partners from “outperform” to “market perform”. They now have a $127.00 price target on the stock, down from $146.00.
• 7/12/2026 – Gilead Sciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/8/2026 – Gilead Sciences had its price target lowered by Morgan Stanley from $168.00 to $166.00. They now have an “overweight” rating on the stock.
• 7/7/2026 – Gilead Sciences had its price target lowered by Royal Bank Of Canada from $122.00 to $120.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Gilead Sciences had its price target lowered by Truist Financial Corporation from $157.00 to $156.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Gilead Sciences was upgraded by HSBC Holdings plc from “hold” to “buy”. They now have a $155.00 price target on the stock, up from $133.00.
• 7/6/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
• 6/16/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
• 6/9/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/8/2026 – Gilead Sciences had its “sector perform” rating reaffirmed by Royal Bank Of Canada.
• 6/1/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Royal Bank Of Canada. They now have a $122.00 price target on the stock.
• 6/1/2026 – Gilead Sciences was upgraded by Royal Bank Of Canada from “hold” to “moderate buy”.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the sale, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 67,000 shares of company stock valued at $8,687,140 in the last 90 days. 0.30% of the stock is currently owned by insiders.

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.